Lipolytics
Unlicensed Fat Dissolving Injections
Phosphatidylcholine / deoxycholate (non-Kybella formulations)
Compounded or unregulated fat-dissolving solutions with serious injury risk
Unlicensed fat-dissolving injections are dangerous for all skin types. The inflammatory tissue destruction caused by unregulated formulations can trigger severe post-inflammatory hyperpigmentation in Fitzpatrick V–VI patients on top of the baseline risks of necrosis and scarring that apply to everyone.
Cheap or unbranded fat-dissolving injections sold at aesthetic clinics that are not the FDA-approved product (Kybella). These might be labelled "PCDC," "lipolysis injections," "fat dissolving cocktail," or similar names. They are not safe. They are not approved. And the documented complications -- skin death (necrosis), permanent scarring, and disfiguring fat atrophy -- are real. The only legitimate fat-dissolving injection for faces is Kybella/Belkyra, and even that has serious risks. Anything else is gambling with your face.
Unlicensed fat-dissolving injections refer to compounded or imported formulations of phosphatidylcholine (PC) and/or deoxycholic acid at unregulated concentrations, administered outside FDA-approved protocols. Unlike Kybella (deoxycholic acid at precisely 10mg/mL, FDA-approved for submental use only), these formulations may contain variable concentrations, unlicensed combinations, or ingredients not studied for safety in human tissue. Case reports and case series document skin necrosis, permanent scarring, ulceration, nerve injury, and fat atrophy occurring with these unlicensed preparations.
- ✓
Skin necrosis and permanent scarring documented in case series of unlicensed fat-dissolving formulations (Rotunda and Kolodney 2006).
- ✓
No standardised safety data for unlicensed formulations; compounding introduces unknown concentration variability.
- ?
Nothing -- no ethical basis for RCTs of unlicensed formulations.
Adverse events associated with non-FDA-approved fat-dissolving injections: a case series
Rotunda & Kolodney · Dermatologic Surgery · 2006
Case series and literature review documenting skin necrosis, permanent scarring, ulceration, nerve injury, and disfiguring fat atrophy following injection of compounded phosphatidylcholine/deoxycholate solutions outside FDA-approved protocols. Unlike Kybella, these formulations have no standardized concentration, no clinical trial safety data, and no regulatory oversight.
PubMed ↗ PMID 16398785| Brand | Manufacturer | What differentiates it | Approval | Pricing |
|---|---|---|---|---|
| Kybella / Belkyra | Allergan (AbbVie) | The only legitimate option for submental fat; confirm vial label before treatment | 2015 | $1,200-2,000/session |
| Aqualyx | Marypharm | CE-marked in Europe; not FDA-approved; weaker evidence base than Kybella; avoid outside properly regulated clinical settings | CE only | Varies |
Full list of studies reviewed15 studies +
- 1.Smith CA, et al. Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists. Dermatology and therapy. 2025.PMID 39751745 ↗
- 2.Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. Journal of the American Academy of Dermatology. 2019.PMID 39751745 ↗
- 3.Bachelot A, et al. Anti-androgen treatments. Annales d'endocrinologie. 2010.PMID 39725212 ↗
- 4.Goodman NF, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2015.PMID 26509855 ↗
- 5.Shaw JC. Hormonal therapies in acne. Expert opinion on pharmacotherapy. 2002.PMID 12083987 ↗
- 6.Manjaly C, et al. Clascoterone for treatment of acne. Drugs of today (Barcelona, Spain : 1998). 2023.PMID 36811407 ↗
- 7.George R, et al. Hormonal therapy for acne. Seminars in cutaneous medicine and surgery. 2008.PMID 18786497 ↗
- 8.Khunger N, et al. Menopausal Acne - Challenges And Solutions. International journal of women's health. 2019.PMID 31754313 ↗
- 9.Husein-ElAhmed H. Management of acne vulgaris with hormonal therapies in adult female patients. Dermatologic therapy. 2015.PMID 25845307 ↗
- 10.Azarchi S, et al. Androgens in women: Hormone-modulating therapies for skin disease. Journal of the American Academy of Dermatology. 2019.PMID 30312645 ↗
- 11.Yemisci A, et al. Effects and side-effects of spironolactone therapy in women with acne. Journal of the European Academy of Dermatology and Venereology : JEADV. 2005.PMID 15752283 ↗
- 12.Bettoli V, et al. Is hormonal treatment still an option in acne today?. The British journal of dermatology. 2015.PMID 15752283 ↗
- 13.Kamangar F, et al. Acne in the adult female patient: a practical approach. International journal of dermatology. 2012.PMID 25627824 ↗
- 14.Feily A, et al. The effect of low-dose isotretinoin therapy on serum androgen levels in women with acne vulgaris. International journal of women's dermatology. 2020.PMID 22994662 ↗
- 15.Shaw JC. Acne: effect of hormones on pathogenesis and management. American journal of clinical dermatology. 2002.PMID 12358558 ↗
Should You Try This?
Probably don't do it
Clinic checklist
Universal
- Check the practitioner is licensed and registered. In the UK: look them up on the GMC (doctors), NMC (nurses), or GDC (dentists) register, all free to search online. In the US: search your state medical board. Takes 2 minutes. If they cannot tell you their regulatory body, leave.
- Ask to see the product box before treatment. It should be factory-sealed with a visible lot number and expiry date. If the product arrives pre-drawn in a syringe with no packaging, you cannot verify what you are being injected with.
- You should receive a written consent form before treatment. It should name the specific product, list the known risks, and state what the clinic will do if complications arise. A single generic form with no product name is not adequate.
- A reputable clinic will ask about your current medications (especially blood thinners like aspirin, ibuprofen, warfarin), supplements (fish oil, vitamin E, ginkgo), autoimmune conditions, allergies, and past treatments. If no one asks, they are skipping a safety step.
- Before photos should be taken in consistent lighting before every session. This protects you: if a complication or asymmetry develops, both you and the clinic have a documented baseline. If a clinic does not take before photos, they are not tracking outcomes.
- Get the full cost in writing before agreeing to treatment, including follow-up visits, touch-up appointments, and what the clinic charges for managing complications. Verbal quotes are not binding.
Procedure-specific
- If considering fat-dissolving injections, ask to see the vial and confirm it is Kybella (US) or Belkyra (EU/Canada); if the product name is anything else, decline.
- Ask the practitioner to confirm the product's regulatory status -- if they cannot confirm it clearly, leave.
- Any offer of "fat dissolving cocktail," "PCDC mix," "lipolysis injection," or similar generic terms is a red flag -- do not proceed.
- Even with legitimate Kybella, understand that the recovery involves severe swelling and nerve injury risk; budget 1-2 weeks of visible recovery per session.
Educational content only. This page summarises published clinical research and is not medical advice. Consult a qualified healthcare provider before making decisions about your care.